Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Several other research analysts have also weighed in on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, January 7th. ValuEngine lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. BidaskClub lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday, January 16th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Collegium Pharmaceutical presently has an average rating of “Buy” and an average target price of $28.50.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The business had revenue of $73.40 million for the quarter, compared to analyst estimates of $72.71 million. During the same quarter last year, the firm earned ($0.54) EPS. Collegium Pharmaceutical’s quarterly revenue was up 579.6% compared to the same quarter last year. Analysts expect that Collegium Pharmaceutical will post -0.14 EPS for the current fiscal year.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $15.56, for a total value of $389,000.00. Following the transaction, the director now owns 286,000 shares of the company’s stock, valued at $4,450,160. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 75,000 shares of company stock worth $1,188,500. Insiders own 13.87% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in COLL. Meeder Asset Management Inc. lifted its stake in Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock valued at $62,000 after buying an additional 3,179 shares in the last quarter. Oregon Public Employees Retirement Fund bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $103,000. Metropolitan Life Insurance Co. NY lifted its stake in Collegium Pharmaceutical by 412.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,124 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 8,954 shares in the last quarter. Advisory Services Network LLC bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $203,000. Finally, IHT Wealth Management LLC bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $219,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.